ForSight VISION4 Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ForSight VISION4 Inc.
Organon's First Move Post Spinout Is A Licensing Deal With ObsEva In Preterm Labor
Ogranon will pay $25m upfront for worldwide commercialization rights to ebopiprant for acute preterm labor, which currently has no approved treatments in the US.
Organon APAC Head On Why World Needs A Company Dedicated To Women’s Health
In this audio interview, Organon’s head for the Asia Pacific region talks to Scrip on the company’s ambitions in the women’s health segment and the outlook for its biosimilars and established brands portfolios.
Alydia Health Prepares US Launch For Maternal Care Device
The Jada system has received 510(k) clearance from the US FDA to treat postpartum hemorrhage and abnormal postpartum uterine bleeding.
Execs On The Move, October 2016
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
- Other Names / Subsidiaries
-
- ForSight Labs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice